Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)

Annalisa Capuano, Cristina Scavone, Cristiana Vitale, Liberata Sportiello, Francesco Rossi, Giuseppe M C Rosano, Andrew J Stewart Coats

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The role of spironolactone and eplerenone in patients with Heart Failure with preserved Ejection Fraction (HFpEF) is not well defined. Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for patients with HFpEF, this review gives an in-depth update on the role of spironolactone and eplerenone and their implications for therapy in the setting of HFpEF. Eleven clinical studies, including seven randomized trials, were reviewed. Two randomized controlled trials evaluated the effect of eplerenone on different end-points, including 6 minute walk distance (6MWD), cardiovascular mortality, non-fatal reinfarction, hospitalization for unstable angina and congestive heart failure. Eplerenone did not affect either 6MWD or event-free survival rates in the overall study population in these two reports. The effects of spironolactone on similar composite endpoints were evaluated in 7 studies in patients with HFpEF. Compared to placebo, hospitalization for heart failure was significantly lower in the spironolactone group and spironolactone was also shown to improve diastolic function and induced beneficial remodeling through a reduction in myocardial fibrosis. The safety profile of spironolactone and eplerenone has been assessed in two recent studies. Data showed that eplerenone and spironolactone are both associated with the occurrence of gynecomastia, mastodynia, and abnormal vaginal bleeding and in addition, they can increase natriuresis and cause renal retention of potassium; furthermore, eplerenone may cause hyperkalemia and promote the onset of metabolic acidosis or hyponatremia. In conclusion although the mineralocorticoid receptor antagonists eplerenone and spironolactone improve clinical outcomes in patients with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for eplerenone, in the treatment of HFpEF.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalInternational Journal of Cardiology
Volume200
DOIs
Publication statusPublished - Sep 23 2015

Fingerprint

Mineralocorticoid Receptor Antagonists
Spironolactone
Heart Failure
Hospitalization
Mastodynia
Gynecomastia
eplerenone
Natriuresis
Hyperkalemia
Uterine Hemorrhage
Hyponatremia
Unstable Angina
Acidosis
Treatment Failure
Disease-Free Survival
Potassium
Fibrosis
Survival Rate
Randomized Controlled Trials
Placebos

Keywords

  • Aldosterone
  • Eplerenone
  • Heart failure
  • HFpEF
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). / Capuano, Annalisa; Scavone, Cristina; Vitale, Cristiana; Sportiello, Liberata; Rossi, Francesco; Rosano, Giuseppe M C; Coats, Andrew J Stewart.

In: International Journal of Cardiology, Vol. 200, 23.09.2015, p. 15-19.

Research output: Contribution to journalArticle

Capuano, Annalisa ; Scavone, Cristina ; Vitale, Cristiana ; Sportiello, Liberata ; Rossi, Francesco ; Rosano, Giuseppe M C ; Coats, Andrew J Stewart. / Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). In: International Journal of Cardiology. 2015 ; Vol. 200. pp. 15-19.
@article{1c7299e4f2564263bcc1085f86b34d7f,
title = "Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)",
abstract = "The role of spironolactone and eplerenone in patients with Heart Failure with preserved Ejection Fraction (HFpEF) is not well defined. Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for patients with HFpEF, this review gives an in-depth update on the role of spironolactone and eplerenone and their implications for therapy in the setting of HFpEF. Eleven clinical studies, including seven randomized trials, were reviewed. Two randomized controlled trials evaluated the effect of eplerenone on different end-points, including 6 minute walk distance (6MWD), cardiovascular mortality, non-fatal reinfarction, hospitalization for unstable angina and congestive heart failure. Eplerenone did not affect either 6MWD or event-free survival rates in the overall study population in these two reports. The effects of spironolactone on similar composite endpoints were evaluated in 7 studies in patients with HFpEF. Compared to placebo, hospitalization for heart failure was significantly lower in the spironolactone group and spironolactone was also shown to improve diastolic function and induced beneficial remodeling through a reduction in myocardial fibrosis. The safety profile of spironolactone and eplerenone has been assessed in two recent studies. Data showed that eplerenone and spironolactone are both associated with the occurrence of gynecomastia, mastodynia, and abnormal vaginal bleeding and in addition, they can increase natriuresis and cause renal retention of potassium; furthermore, eplerenone may cause hyperkalemia and promote the onset of metabolic acidosis or hyponatremia. In conclusion although the mineralocorticoid receptor antagonists eplerenone and spironolactone improve clinical outcomes in patients with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for eplerenone, in the treatment of HFpEF.",
keywords = "Aldosterone, Eplerenone, Heart failure, HFpEF, Spironolactone",
author = "Annalisa Capuano and Cristina Scavone and Cristiana Vitale and Liberata Sportiello and Francesco Rossi and Rosano, {Giuseppe M C} and Coats, {Andrew J Stewart}",
year = "2015",
month = "9",
day = "23",
doi = "10.1016/j.ijcard.2015.07.038",
language = "English",
volume = "200",
pages = "15--19",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF)

AU - Capuano, Annalisa

AU - Scavone, Cristina

AU - Vitale, Cristiana

AU - Sportiello, Liberata

AU - Rossi, Francesco

AU - Rosano, Giuseppe M C

AU - Coats, Andrew J Stewart

PY - 2015/9/23

Y1 - 2015/9/23

N2 - The role of spironolactone and eplerenone in patients with Heart Failure with preserved Ejection Fraction (HFpEF) is not well defined. Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for patients with HFpEF, this review gives an in-depth update on the role of spironolactone and eplerenone and their implications for therapy in the setting of HFpEF. Eleven clinical studies, including seven randomized trials, were reviewed. Two randomized controlled trials evaluated the effect of eplerenone on different end-points, including 6 minute walk distance (6MWD), cardiovascular mortality, non-fatal reinfarction, hospitalization for unstable angina and congestive heart failure. Eplerenone did not affect either 6MWD or event-free survival rates in the overall study population in these two reports. The effects of spironolactone on similar composite endpoints were evaluated in 7 studies in patients with HFpEF. Compared to placebo, hospitalization for heart failure was significantly lower in the spironolactone group and spironolactone was also shown to improve diastolic function and induced beneficial remodeling through a reduction in myocardial fibrosis. The safety profile of spironolactone and eplerenone has been assessed in two recent studies. Data showed that eplerenone and spironolactone are both associated with the occurrence of gynecomastia, mastodynia, and abnormal vaginal bleeding and in addition, they can increase natriuresis and cause renal retention of potassium; furthermore, eplerenone may cause hyperkalemia and promote the onset of metabolic acidosis or hyponatremia. In conclusion although the mineralocorticoid receptor antagonists eplerenone and spironolactone improve clinical outcomes in patients with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for eplerenone, in the treatment of HFpEF.

AB - The role of spironolactone and eplerenone in patients with Heart Failure with preserved Ejection Fraction (HFpEF) is not well defined. Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for patients with HFpEF, this review gives an in-depth update on the role of spironolactone and eplerenone and their implications for therapy in the setting of HFpEF. Eleven clinical studies, including seven randomized trials, were reviewed. Two randomized controlled trials evaluated the effect of eplerenone on different end-points, including 6 minute walk distance (6MWD), cardiovascular mortality, non-fatal reinfarction, hospitalization for unstable angina and congestive heart failure. Eplerenone did not affect either 6MWD or event-free survival rates in the overall study population in these two reports. The effects of spironolactone on similar composite endpoints were evaluated in 7 studies in patients with HFpEF. Compared to placebo, hospitalization for heart failure was significantly lower in the spironolactone group and spironolactone was also shown to improve diastolic function and induced beneficial remodeling through a reduction in myocardial fibrosis. The safety profile of spironolactone and eplerenone has been assessed in two recent studies. Data showed that eplerenone and spironolactone are both associated with the occurrence of gynecomastia, mastodynia, and abnormal vaginal bleeding and in addition, they can increase natriuresis and cause renal retention of potassium; furthermore, eplerenone may cause hyperkalemia and promote the onset of metabolic acidosis or hyponatremia. In conclusion although the mineralocorticoid receptor antagonists eplerenone and spironolactone improve clinical outcomes in patients with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for eplerenone, in the treatment of HFpEF.

KW - Aldosterone

KW - Eplerenone

KW - Heart failure

KW - HFpEF

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=84941952548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941952548&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.07.038

DO - 10.1016/j.ijcard.2015.07.038

M3 - Article

C2 - 26404747

AN - SCOPUS:84941952548

VL - 200

SP - 15

EP - 19

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -